银屑病关节炎生物制剂短期应答不受治疗启动时病程影响
该研究纳入2000至2025年启动生物制剂治疗的228例银屑病关节炎患者,按诊断后2年内启动(早期组71例)或更晚启动(延迟组157例)分组,倾向评分回归调整后未发现两组6个月DAPSA应答≥50%或PASI75存在差异,提示短期应答不受启动时病程影响。
要点
- 诊断后2年内启动生物制剂与更晚启动者6个月DAPSA应答≥50%无差异。
- 早期与延迟启动生物制剂者6个月PASI75应答亦无差异。
- 早期治疗能否长期阻止关节损伤进展尚待确定。
核心结论
- 银屑病关节炎患者生物制剂短期应答在早期启动与延迟启动之间未见差异。
研究设计与样本
- 纳入2000至2025年启动生物制剂治疗的生物制剂初治银屑病关节炎患者228例,早期组为诊断后2年内启动者71例,延迟组为更晚启动者157例。
- 主要结局为6个月时DAPSA评分较基线改善≥50%,次要结局为6个月时PASI75。
- 采用逻辑回归分析早期治疗与6个月疾病结局的关联,并用倾向评分校正基线组间差异。
主要发现
- 倾向评分回归调整分析未提示诊断后2年内治疗与更晚治疗者在6个月应答上存在差异。
- 不同年代从银屑病关节炎诊断到生物制剂治疗的时间存在显著差异。
关键数值与推荐
- 早期治疗定义为银屑病关节炎诊断后2年内启动生物制剂治疗。
- 主要结局为6个月时DAPSA评分较基线降低≥50%。
- 次要结局为6个月时PASI75,即PASI评分较基线改善≥75%。
临床怎么用
- 对于生物制剂初治的银屑病关节炎患者,不应仅因病程较长而排除生物制剂治疗。
- 短期疗效评估可在启动生物制剂后6个月时参考DAPSA应答≥50%与PASI75。
局限性
- 早期治疗能否预防长期关节损伤进展仍未确定。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to determine whether the short-term response to biologics in biologic-naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. METHODS: Patients with PsA who started on biologic therapy from the year 2000 to 2025 were included for analysis. Patients were considered in the early treatment group if they had started on biologic therapy within two years of PsA diagnosis; otherwise, they were considered in the delayed treatment group. The primary outcome was ≥50% reduction in the Disease Activity Index for Psoriatic Arthritis (DAPSA) score at six months. The secondary outcome was Psoriasis Area and Severity Index (PASI) 75, defined as ≥75% improvement in the PASI score at six months. Logistic regression was used to examine the association between early treatment and disease outcomes at six months. Propensity scores were used to account for differences between the groups at the baseline visit. RESULTS: Of the 228 included patients, 71 patients were in the early treatment group, and 157 patients were in the delayed treatment group. There were significant differences in the time from PsA diagnosis to biologic treatments over the decades. The propensity score regression adjusted analysis did not suggest a difference in response at six months between those treated within two years of diagnosis and those treated later. CONCLUSION: Short-term response to biologic therapy in patients with PsA does not appear to differ between those treated early or later in the disease course. It remains to be determined whether early treatment prevents progression of joint damage in the longer-term.
引用
- Cho SM, Gao S, Pereira D, et al. Short-Term Response to Biologic Therapy in Psoriatic Arthritis Is Not Influenced by Disease Duration at Initiation of Therapy. Arthritis Care Res (Hoboken). 2026. PMID: 42482404. doi:10.1002/acr.80120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。